Baseline disease activity by BMI (kg/m2).
| MTX Monotherapy, N = 284 | ETN Monotherapy, N = 284 | MTX+ETN Combination Therapy, N = 283 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| BMI, ≤ 30 | BMI, > 30 | Pa,b, BMI ≤ 30 vs > 30 | BMI, ≤ 30 | BMI, > 30 | Pa,b, BMI ≤ 30 vs > 30 | BMI, ≤ 30 | BMI, > 30 | Pa,b, BMI ≤ 30 vs > 30 | |
| PsA duration, yrs | 3.9 (0.6) | 3.4 (0.6) | – | 2.8 (0.4) | 3.5 (0.7) | – | 3.9 (0.6) | 1.9 (0.4) | 0.01 |
| SJC66 | 11.1 (0.7) | 14.9 (0.9) | 0.001 | 11.2 (0.7) | 11.9 (1.0) | – | 10.1 (0.6) | 12.7 (1.0) | 0.02 |
| TJC68 | 18.4 (1.2) | 23.6 (1.3) | 0.003 | 17.3 (1.1) | 20.7 (1.3) | – | 18.0 (1.1) | 22.6 (1.5) | 0.01 |
| PGA, 0–100 | 57.1 (1.6) | 60.2 (1.7) | – | 58.2 (1.5) | 58.7 (1.6) | – | 56.6 (1.4) | 59.8 (1.6) | – |
| CRP, mg/L | 9.6 (1.4) | 11.5 (1.3) | – | 10.5 (1.5) | 11.1 (1.1) | – | 8.0 (1.0) | 9.6 (0.9) | – |
| SPARCC enthesitis | 3.3 (0.3) | 4.4 (0.4) | 0.03 | 3.6 (0.3) | 3.8 (0.4) | – | 3.6 (0.3) | 4.8 (0.4) | 0.04 |
| sPGA | 2.5 (0.1) | 2.7 (0.1) | – | 2.5 (0.1) | 2.8 (0.1) | 0.02 | 2.5 (0.1) | 2.5 (0.1) | – |
| sPGA status | |||||||||
| < 2, n (%) | 24 (8.5) | 24 (8.5) | 25 (8.8) | 15 (5.3) | 27 (9.5) | 25 (8.8) | |||
| ≥ 2, n (%) | 120 (42.3) | 113 (39.8) | – | 128 (45.1) | 116 (40.8) | – | 133 (47.0) | 98 (34.6) | – |
| BSA, % | 12.3 (1.5) | 13.1 (1.7) | – | 10.9 (1.2) | 10.4 (1.2) | – | 10.2 (1.1) | 11.5 (1.6) | – |
| BSA | |||||||||
| < 3%, n (%) | 42 (14.8) | 50 (17.6) | – | 58 (20.4) | 47 (16.5) | – | 62 (21.9) | 44 (15.5) | – |
| ≥ 3%, n (%) | 104 (36.6) | 88 (31.0) | – | 95 (33.5) | 84 (29.6) | – | 98 (34.6) | 79 (27.9) | – |
| HAQ-DI | 1.2 (0.1) | 1.4 (0.1) | 0.03 | 1.1 (0.1) | 1.3 (0.1) | 0.003 | 1.1 (0.1) | 1.3 (0.1) | 0.002 |
| PtGA, 0–100 | 58.3 (2.0) | 63.2 (1.7) | – | 63.2 (1.9) | 62.6 (1.8) | – | 61.0 (1.7) | 60.9 (1.8) | – |
| PtGAJP, 0–100 | 54.9 (1.8) | 57.4 (1.8) | – | 55.0 (1.9) | 58.3 (1.8) | – | 55.0 (1.8) | 56.5 (1.8) | – |
| SF-36 PCS | 37.1 (0.7) | 33.9 (0.7) | 0.001 | 38.7 (0.7) | 36.7 (0.7) | 0.04 | 38.3 (0.7) | 36.2 (0.8) | – |
| SF-36 MCS | 45.6 (1.0) | 44.7 (1.1) | – | 46.1 (1.0) | 44.0 (1.1) | – | 45.3 (0.9) | 47.5 (1.0) | – |
Values are expressed as mean (SE) unless otherwise stated.
↵aP values are nominal.
↵bOnly P values ≥ 0.05 are shown. BSA: body surface area; CRP: C-reactive protein; ETN: etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCS: Mental Component Summary; MTX: methotrexate; PCS: Physical Component Summary; PGA: physician global assessment; PsA: psoriatic arthritis; PtGA: patient global assessment of disease activity; PtGAJP: patient global assessment of joint pain; SE: standard error; SF-36: 36-item Short Form Health Survey; SJC66: swollen joint count in 66 joints; SPARCC: Spondyloarthritis Research Consortium of Canada; sPGA: static physician global assessment (of psoriasis); TJC68: tender joint count in 68 joints.